Nicotinic acid (prescription NIASPAN extended-release tablets) × Mean LDL-C percentage change in primary hypercholesterolaemia

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Separate questionWhich NIASPAN LDL-C contrast is retained?Required	The assessed claim is mean LDL-C percentage change in primary hypercholesterolaemia, limited to oral NIASPAN nicotinic acid extended-release tablets at 2000 mg/day versus diet plus placebo over 16 weeks including titration. S15 S16	The exact assessed claim, claim conditions and editorial scope support this single question.	Exact locations for the assessed claim, claim conditions and editorial scope, and the canonical URL.	First fix the question and report-eligibility table, then check whether other formulations, TG or clinical-event questions have entered the scope.
2	Partly verified	Full text not readStored summary read	N02 · Population and selectionAre eligibility criteria and baseline characteristics verified?Required	The population has primary hypercholesterolaemia with LDL-C >160 mg/dL despite dietary management. Retained summaries distinguish this from deficiency correction and add-on statin strategies, but the retained abstract/regulatory-table summaries do not verify detailed eligibility or baseline tables. S15 S16	The diagnosis and LDL entry criterion are stated; detailed recruitment and baseline composition remain unresolved.	The original article’s inclusion/exclusion criteria, age, baseline table and preceding dietary procedures.	Check recruitment criteria and baseline tables against the target and included populations, including selection limitations.
3	Met	Full text not readStored summary read	N03 · Nutritional statusDoes this trial concern correction of B3 deficiency?Required (population boundary)	The retained record states that the trial did not select nutritional deficiency and that the abstract/tables used contained no diagnostic B3 concentration data. S15 S16	The non-deficiency selection boundary and the limited concentration-reporting scope were verified.	Deficiency-based selection, baseline B3 concentrations and eligibility definitions.	Check whether original recruitment criteria required deficiency; do not pool deficiency-correction evidence as a high-LDL treatment effect.
4	Met	Full text not readStored summary read	N04 · Ingredient and formulationWhat are the selected ingredient, formulation and route?Required	The original records identify oral NIASPAN nicotinic acid extended-release and record that other niacin forms are not equivalent. S15 S16	Retained ingredient, formulation and route identities agree.	Original labelling and product identity for NIASPAN ingredient, ER formulation and oral route.	Link product/formulation definitions to result tables and exclude interchange at the same mg dose with immediate-release, sustained-release, no-flush products or nicotinamide.
5	Partly verified	Full text not readStored summary read	N05 · Dose and actual exposureAre the target dose, titration and actual administration history verified?Required	The key contrast is 2000 mg/day and the label period includes 4-week titration. A 1000 mg arm is also present, but detailed titration and administration histories are unconfirmed. S15 S16	The target dose and titration-inclusive definition were verified; detailed actual exposure is unavailable.	Arm-specific titration schedules, administration/stopping histories and actual doses.	Reconstruct exposure during titration and maintenance, then compare actual doses and deviations with intended prescribing.
6	Met	Full text not readStored summary read	N06 · Comparator strategyWhat is the main comparator strategy?Required	The selected comparator is matched placebo on the same dietary-treatment background. Use the contemporaneous fixed-dose comparison in Table 3, without mixing the dose-escalation table at other times. S15 S16	The comparator conditions and the current article/regulatory-table comparison scope are explicit.	The common dietary treatment, placebo composition and contemporaneous Table 3 comparison.	Compare intervention/control strategies and exclude add-on statin TG strategies and other times in the dose-escalation table.
7	Partly verified	Full text not readStored summary read	N07 · Duration and phase linkageIs the linkage between abstract and regulatory-table periods/phases verified?Required	FDA Table 3 covers 16 weeks including 4-week titration; the publisher abstract describes 12 weeks of treatment. The original citation does not assert exact phase linkage beyond the label definition. S15 S16	Both source definitions are explicit, but detailed phase linkage is unconfirmed.	Original article visit schedules, titration/maintenance phases and an FDA trial-family crosswalk.	Compare timelines and visit schedules side by side to verify phase linkage; do not arbitrarily adjust different durations.
8	Met	Full text not readStored summary read	N08 · Endpoint and unitWhat are the selected outcome measure and unit?Required	The selected endpoint is mean LDL-C percentage change from baseline at 16 weeks in FDA Table 3. Arm values are percentages; the original arithmetic between-arm contrast is in percentage points. S15 S16	The endpoint, mean percentage change and units are explicit in the original calculation record and claim conditions.	Table 3 mean percentage-change definition, units and baseline reference.	Check table headings, footnotes and measures against original material; record differences between means/medians and concentration/%/percentage points.
9	Partly verified	Full text not readStored summary read	N09 · Design and allocationAre the actual design, allocation and concealment implementation verified?Required	The S16 abstract describes a randomized double-blind fixed-dose placebo-controlled design. Allocation-concealment implementation remains unverified without the article full text. S16	The design description is verified; implementation details remain unresolved.	Original methods for random sequence generation, allocation concealment and the baseline table.	Compare sequence generation, enrolment/allocation procedures and concealment implementation with original methods, separating design labels from implementation verification.
10	Unverified	Full text not readStored summary read	N10 · Maintenance of blindingAre maintenance of blinding and arm-specific assessment information verified?Required	The abstract confirms a double-blind design, but checks of maintained blinding remain unverified without full text. Flushing warnings are not converted into evidence of actual blinding failure. S15 S16	The retained scope lacks the required actual blinding checks/assessment procedures.	Participant, staff and assessor blinding procedures and assessments of maintained blinding.	Compare who was blinded, blinding checks and assessor knowledge with original methods, considering limitations for objective lipid outcomes.
11	Partly verified	Full text not readStored summary read	N11 · Co-treatment and dietAre individual co-treatment and dietary exposures verified?Required	The dietary-treatment background and 2000 mg/day study drug are verified, but total diet and individual concurrent vitamin use are unconfirmed. S15 S16	The common treatment scope was verified; actual individual exposures remain unresolved.	Arm-specific total diet, concomitant drugs/vitamins, rescue treatment and change histories.	Extract co-treatment and dietary records by arm and review their handling in intervention strategies and selected analyses.
12	Unverified	Full text not readStored summary read	N12 · Adherence and treatment deviationsAre actual adherence and the analytical handling of treatment deviations verified?Required	The original assessment verified trial dose and dietary comparator but left detailed actual adherence unconfirmed. S16	Arm-specific adherence, treatment changes and analytical handling records were not acquired.	Arm-specific adherence, stopping/dose changes and handling rules.	Link adherence/stopping tables to actual analysis populations and review differences between assignment-effect and adherence-effect interpretations.
13	Partly verified	Full text not readStored summary read	N13 · Measurement proceduresAre the LDL-C assay and arm-specific measurement procedures verified?Required	The original assessment describes objective blood-lipid markers. The retained summary read in this work does not verify detailed assays or specimen/sampling conditions. S15 S16	The measurement target is verified; procedural details remain unresolved.	Original LDL-C assay, specimen/blood-sampling conditions and visit-specific measurement procedures.	Link the assay and sampling/visit schedules to result tables and review arm-specific differences in methods and timing.
14	Met	Full text not readStored summary read	N14 · Arm-specific observationsWhat are the LDL-C values for the two arms at the same time in Table 3?Required	Original Table 3 reports mean percentage changes of −14% in the 2000 mg arm and −1% with placebo. The article abstract agrees at −14% for 2000 mg LDL-C. S15 S16	The same arm-specific observations are retained in the current text and original calculation record.	FDA Table 3 arm-specific values/footnotes and the article’s 2000 mg LDL result.	Re-extract the agreeing 2000 mg LDL values against the original table/abstract’s arm, endpoint and period definitions.
15	Met	Full text not readStored summary read	N15 · Historical contrastWhat does the retained −13 percentage-point value represent?Required	−13 percentage points is the arithmetic contrast between −14% and −1% in the original ChatGPT calculation record. Its status is verification of the existing between-arm arithmetic contrast only; SE, SD, degrees of freedom and CI are null. S15 S16	The original arithmetic-only definition and prohibited conversions are directly connected.	Original difference, unit, method and prohibited-conversion records.	Check the source, common time and direction of the retained arithmetic and whether wording transfers it to an adjusted estimate or clinical risk.
16	Unverified	Full text not readStored summary read	N16 · Effect of interest and analysisAre the analysis population and model for the LDL-C contrast verified?Required	The original records verified only the arithmetic contrast; exact analysed, completed and dropout n and missing-data methods were unconfirmed. Conversion to an adjusted causal difference is also prohibited. S15 S16	The original article full text needed to verify exact analysis methods, populations and models is currently unavailable in the retained material.	Article analysis populations, estimands, models, adjustment and table-specific analysis methods.	Link methods and participants to arm-specific result tables and compare with the effect of interest and missing-data/deviation handling.
17	Partly verified	Full text not readStored summary read	N17 · Allocation-to-analysis denominatorsAre denominators from allocation through analysis verified for each arm?Required	The trial total of 122 includes a 1000 mg arm; baseline n for the main contrast is 41 versus 40. The original sample-size role is baseline n, with completed/analysed sample sizes unverified. S15 S16	Total and baseline denominators are verified; outcome-specific analysis flow remains unresolved.	Arm-specific recruitment, allocation, completion, analysis and dropout flow, and Table 3 analysis n.	Reconstruct each arm’s participant flow over time and verify correspondence between total/baseline samples and outcome-specific analysis denominators.
18	Unverified	Full text not readStored summary read	N18 · Missing-data handlingAre the reasons for missing data/dropout and their handling verified?Required	The original assessment’s missing-data and unresolved-issue records state that exact analysed, completed and dropout n and missing-data methods remain unconfirmed because the full text was not accessed. S16	The retained scope lacks the required loss/handling data.	Arm-specific dropout reasons, missing LDL-C and imputation/sensitivity analyses.	Compare missing-data tables with analysis methods and review whether results under alternative assumptions are available.
19	Unverified	Full text not readStored summary read	N19 · Dispersion and CIAre dispersion and the between-arm CI reported for LDL-C percentage change at the same time?Required	Standard error, change-score standard deviation, degrees of freedom, confidence level and interval are null. The retained record states that selected regulatory tables do not provide corresponding percentage-change dispersion or a lipid-contrast CI; Table 5 IQR and cardiovascular HR CIs were not substituted. S15 S16	Dispersion and CI for the same analysis were not acquired within the selected regulatory-table/abstract scope.	Arm-specific percentage-change dispersion, analysis n, between-arm CI and derivation methods.	Directly verify dispersion/intervals for the relevant analysis and check for substitution of another table’s IQR or a cardiovascular HR CI.
20	Partly verified	Full text not readStored summary read	N20 · Testing and significanceAre the exact P value and test definition verified?Required	The original product information explicitly states that the table’s P<0.05 is not an exact P, CI or SD. Testing/adjustment details remain unverified in the current material. S15	The reported threshold is retained; exact testing/adjustment remains unresolved.	Table 3 testing footnotes, exact P and multiplicity/adjustment methods.	Verify test definitions, analysis populations and comparisons subject to adjustment; do not calculate CI/dispersion from the threshold.
21	Unverified	Full text not readStored summary read	N21 · Important differenceCan the between-arm interval be interpreted against a justified important difference?Required (precision interpretation)	The original imprecision assessment retains unconfirmed lipid between-arm CI/SD and EX(a), without converting them to E0 or failure to reach an MCID. Established clinical benefit is not overstated. S15 S16	The current material lacks a verified CI for this contrast and a justified important-difference criterion.	The LDL-C contrast CI, evidence for an important difference in this question and interpretation limits.	Review whether a justified important difference and the relevant interval are provided; otherwise, do not judge sufficiency from significance alone.
22	Unverified	Full text not readStored summary read	N22 · Plans and registrationDo reported endpoints, times and analyses agree with the original plan?Required	The evidence list’s registration field is null; the text does not claim to have read initial registration or a protocol. The abstract alone did not verify agreement with a registered 1st (primary) endpoint. S15 S16	The required original plan is absent from the retained inputs.	Initial registration, protocol, analysis plan and amendment history.	Compare prespecified endpoints, times and analyses in original plans with result tables/articles to review changes and possible selective reporting.
23	Partly verified	Full text not readStored summary read	N23 · Reports and trial familyAt what level are the article and label linked to the same trial family?Required	The S16 Morgan 1996 trial with 122 participants is strongly linked to S15 Table 3 by design/n/dose. The original citation limits this to less than a patient-level crosswalk. Original R1 records avoidance of double-counting the same trial arms. S15 S16	There is strong linkage evidence for the same key contrast, but no detailed trial/participant crosswalk.	Trial identifiers and population/arm/time crosswalks between the article and FDA trial tables.	Review report–trial–outcome correspondence, distinguishing repeated citations of the same family from unconfirmed detailed links.
24	Unverified	Full text not readStored summary read	N24 · Independent replicationIs independent replication of this question verified?Supplementary; required for replication claims	Original R1 records avoiding double-counting the same trial arms. Multiple trials in the manufacturer table were not converted to R2 without verifying independent authors and funding. S15 S16	Independent author/funding records and unique result tables for the direct question were not acquired in the current inputs.	Unique families, outcomes, funding and authorship for additional eligible trials.	Compare eligible families, remove duplicate reports and record differences in conditions and unverified independence.
25	Unverified	Full text not readStored summary read	N25 · Funding and COIAre research funding, product provision and author interests verified?Supplementary; required for independence claims	The complete original article funding/COI statements were not accessed. Original I1 with uncertainty establishes neither manufacturer-only nor independent research. S16	The full declaration text is absent from the current retained scope.	Complete original article funding, product provision, employment/patents and COI declarations.	Compare original declarations with authors/institutions and study families, recording verified interests separately from uncertainty.
26	Conflicting data	Full text not readStored summary read	N26 · Inconsistent reportsAre the causes of inconsistent reports for other doses/endpoints verified?Required	The retained record states that some publisher-abstract and regulatory-table values disagree, including 1000 mg LDL percentage change. Only the agreeing 2000 mg LDL −14% and each duration definition were adopted; inconsistencies of unknown cause were not asserted to be rounding. S15 S16	The original inconsistency review explicitly records disagreement and unconfirmed causes.	Relevant original publisher-abstract/regulatory-table data, phases/denominators and corrections for 1000 mg LDL, TG and related values.	Compare dose, measure, time and denominator for each inconsistent item, distinguishing conflicting reports of the same contrast from values under different conditions.
27	Not applicable	Full text not readStored summary read	N27 · Extension to clinical eventsDoes LDL-C change answer whether myocardial infarction or mortality is prevented?Supplementary; required for clinical-event extensions	The original key interpretation and reader answer distinguish lipid decreases from patient clinical benefit and do not interpret them as reduced myocardial infarction or mortality. S15 S16	The current main question concerns marker change and has not been extended to event prevention.	Direct event studies with the same strategy/population if extending to events or mortality.	If an extension is claimed, review event-study populations, formulations, comparators and durations in a separate eligibility table.
28	Not applicable	Full text not readStored summary read	N28 · Dose and long-term extensionsDoes the result answer questions about optimal dose, long-term maintenance or specific subgroups?Supplementary; required for the relevant extension	The current scope is 2000 mg/day versus diet plus placebo over 16 weeks including titration. The 1000 mg arm is a supporting record; do not create a pooled mean, optimal dose or long-term effect. S15 S16	Optimal dose, long-term persistence and subgroups are extensions of the selected question and are not claimed in this table.	Direct dose comparisons, long-term follow-up and prespecified subgroup/interaction data if extending the claim.	Review direct comparisons, follow-up and interactions separately for extensions outside the original question; do not average supporting arms of the same trial.
29	Partly verified	Full text not readStored summary read	N29 · Harm collection and denominatorsAre arm-specific harm collection, event/person counts and stopping denominators verified for the key trial?Supplementary; required for harm/safety claims	Warnings about flushing and elevated liver enzymes, glucose and urate at prescription doses are retained. Arm-specific AE denominators in the key small trial are unconfirmed; FDA2020 pooled data were not used as this trial’s event rates. S15	The official document’s warning scope is linked; systematic collection/counts in the selected trial remain unresolved.	The key trial’s AE definitions, collection, people/events, stopping, exposure time and arm-specific denominators.	Link arm-specific safety tables/collection procedures to follow-up and check which trials contribute to FDA pooled data.
30	Unverified	Full text not readStored summary read	N30 · Harm timing and alternativesAre temporal order, co-treatment and alternative comparative causes verified for harms in the selected trial?Supplementary; required for harm causality/scope	The original safety detail retains warnings about pharmacological-dose nicotinic acid but leaves selected-trial arm-specific harm denominators unconfirmed. Actual temporal order, co-treatment/alternatives and stopping/recovery outcomes are not verified in these inputs. S15	The current warning summary does not provide selected-trial timing, comparative or alternative-cause data.	Trial AE onset, stopping/recovery, concurrent medication/baseline disease, comparisons and long-term vulnerable-group data.	Link exposure/event timelines and co-treatment to actual counts and review the possible scope of causal, frequency and long-term extrapolation.
31	Partly verified	Full text not readStored summary read	N31 · Laboratory interferenceWithin what scope was reported laboratory interference verified?Supplementary; required for interference claims	The current text includes specific laboratory-interference warnings and the original citation links FDA Section 7.6, printed page 9. This summary lacks assay-specific details and evidence of actual LDL-C interference in the selected trial. S15	Warnings and historical locations are verified; assay-specific details and actual trial interference remain unresolved.	FDA7.6 assay-specific interference conditions and the original trial LDL-C assay/interference observations.	Compare assay-specific conditions in the official document with original measurement methods, separating general warnings from interference observed in the trial.
32	Met	Full text not readStored summary read	N32 · Material readingWhich material was actually read in this work?Required	The complete original-byte retained summary was read in this work. Historical access was S15 regulatory PDF text/selected table screenshots and S16 abstract/bibliography. External PDFs and publisher/DOI pages were not attempted, acquired or read in this work; individual access dates remain null. S15 S16	Current actual reading and original recorded access levels were separately connected by material.	Current input SHA, material type/URL, historical access locations, individual access dates and global review date.	Compare existence, acquisition, reading status and original locations by report, separating blue summary links from unread external full texts.
33	Met	Full text not readStored summary read	N33 · Verification scope and historyWhat search, correction and history scope is retained?Required	The original search is described as 2026-09-14 web indexing, a supplied index of 3081 entries/related originals and direct publisher/FDA/NHLBI sources. It was not a complete systematic PubMed search or exhaustive search of unpublished material; original wording/references for 5 corrections remain unchanged. S15 S16	The reported scope of earlier searches/corrections and the boundary of work not performed now were verified.	Existing search records, 5 corrections, inputs used and the unpublished/registration verification scope.	Check the scope actually retained for search logs/corrections and limit uncertainty statements to the relevant sections/dates.
34	Met	Full text not readStored summary read	N34 · Original assessment and table statusHow are original assessments/numbers distinguished from table-review status?Required (display boundary)	Original grade C/score 46, B/S/R1/I1/EX/B1/CX, caution and all nulls/corrections/historical arithmetic remain unchanged. Condition states indicate item-specific verification within current retained material, not a new clinical assessment or success probability. S15 S16	Original current values and limits of table conversion/condition states were separately recorded.	Original grade/score/axes, calculation records, gaps, corrections and original internal-review metadata.	Compare the complete retained summary with derived tables, separating technical checks from content review of unchanged original values/nulls, inconsistencies and condition states.

No items match your search or filter.

34 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence review date: 2026-09-14
Scope actually checked: Retained Korean/English summaries and case-specific condition/application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: The date retained material was checked, not the date of a latest clinical-literature search.
Population: Primary hypercholesterolaemia with LDL-C >160 mg/dL despite dietary management. This is distinct from deficiency correction and an add-on statin strategy.
Ingredient, formulation and route: Nicotinic acid (prescription NIASPAN extended-release tablets); NIASPAN nicotinic acid extended-release tablets, distinct from nicotinamide and inositol hexanicotinate; oral
Dose: Key contrast: 2000 mg/day; other arms in the same trial, including 1000 mg/day, are supporting records and are not averaged together.
Comparator: Matched placebo on the same dietary-treatment background. Compare the key fixed dose of 2000 mg with contemporaneous placebo; do not mix in other times from the dose-escalation table.
Measured outcome: Mean LDL-C percentage change from baseline at 16 weeks in regulatory Table 3. The article abstract alone does not verify agreement with an originally registered 1st (primary) endpoint.
Duration: Regulatory table: 16 weeks including 4-week titration. The publisher abstract describes 12 weeks of treatment; retain both definitions.
Questions outside this scope: Deficiency correction, add-on statin TG strategies and other vitamin B3 formulations; Extensions to myocardial infarction, mortality, optimal dose, long-term effects or subgroups

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S15 · NIASPAN (niacin extended-release tablets), FDA prescribing information revised 09/2020

Official source

Material type: Regulatory re-report of the key LDL trial; other trials/pooled safety in the full label have separate scopes
Materials actually read: Retained Korean/English summaries and case-specific condition/application records were read. External PDFs, abstracts, full texts and registration were not attempted, acquired or read in this work.
Findings recorded in the stored summary: Retain Table 3 mean LDL-C percentage change of −14% with 2000 mg, contemporaneous placebo −1% and the existing −13 percentage-point contrast. The 16 weeks include 4-week titration. Baseline 41/40 are not analysis n; dispersion/CI and trial-specific AE denominators are unverified. Do not fill gaps with other tables, medians or pooled safety.
Record level: Historical review summaries and source locations are retained. This is not renewed verification of external originals or a new clinical assessment.
Study overlap and independent replication: S15 and S16 are strongly linked by matching design, sample size and dose to the key NIASPAN-Morgan-122-supported trial. A patient-level crosswalk is unverified. The 2 reports are not counted as 2 independent trials/replications; other trials and pooled safety in the full label have separate scopes. Overall unique-study, participant and independent direct-replication counts are unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
FDA prescribing-information full PDF	Current public availability unverified	External access not attempted; not acquired	Unread	Regulatory re-report of the key LDL trial; other trials/pooled safety in the full label have separate scopes; external originals were not attempted, acquired or read. Only the retained URL is provided; access, acquisition and reading were not attempted in this work. Individual historical access dates are unrecorded and distinct from the original evidence review date.
Retained bibliographic, evidence and manuscript summary	Internally retained summary	Retained copy acquired; summary read	Retained existing review summary read	The retained summary was acquired and read. This is not an original-byte copy of a clinical full text.

S16 · Morgan et al. Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients with Hypercholesterolemia: A Placebo-controlled Trial

Official source

Material type: Article abstract/bibliography for the same key trial; patient-level crosswalk unverified
Materials actually read: Retained Korean/English summaries and case-specific condition/application records were read. External PDFs, abstracts, full texts and registration were not attempted, acquired or read in this work.
Findings recorded in the stored summary: A randomized double-blind fixed-dose placebo-controlled trial with 122 participants in total. The abstract’s −14% LDL result at 2000 mg agrees with the regulatory table; retain the abstract’s 12-week definition and the label’s 16 weeks including titration. Full funding/COI, exact analysis/missing-data handling and causes of inconsistencies for other doses/endpoints are unverified.
Record level: Historical review summaries and source locations are retained. This is not renewed verification of external originals or a new clinical assessment.
Study overlap and independent replication: S15 and S16 are strongly linked by matching design, sample size and dose to the key NIASPAN-Morgan-122-supported trial. A patient-level crosswalk is unverified. The 2 reports are not counted as 2 independent trials/replications; other trials and pooled safety in the full label have separate scopes. Overall unique-study, participant and independent direct-replication counts are unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher article abstract/bibliography webpage	Current public availability unverified	External access not attempted; not acquired	Unread	Article abstract/bibliography for the same key trial; patient-level crosswalk unverified; external originals were not attempted, acquired or read. Only the retained URL is provided; access, acquisition and reading were not attempted in this work. Individual historical access dates are unrecorded and distinct from the original evidence review date.
Retained bibliographic, evidence and manuscript summary	Internally retained summary	Retained copy acquired; summary read	Retained existing review summary read	The retained summary was acquired and read. This is not an original-byte copy of a clinical full text.
DOI bibliographic entry	Current public availability unverified	External access not attempted; not acquired	Unread	An article-identifier entry, not evidence of full-text acquisition or actual reading. Only the retained URL is provided; access, acquisition and reading were not attempted in this work. Individual historical access dates are unrecorded and distinct from the original evidence review date. The DOI entry does not automatically inherit historical abstract/bibliography access.

Report counts versus independent study counts

S15 and S16 are strongly linked by matching design, sample size and dose to the key NIASPAN-Morgan-122-supported trial. A patient-level crosswalk is unverified. The 2 reports are not counted as 2 independent trials/replications; other trials and pooled safety in the full label have separate scopes. Overall unique-study, participant and independent direct-replication counts are unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which NIASPAN LDL-C contrast is retained?

Required materials and conditions: Exact locations for the assessed claim, claim conditions and editorial scope, and the canonical URL.
Conditions for verification: Connect the exact assessed claim, formulation, population, diet plus placebo, 2000 mg/day and 16 weeks including titration as one question.
Requirement and applicability: Required
Application exceptions: The subclaim array is empty. Do not automatically generate tables for other doses/endpoints or rewrite 128/2346.
Why this condition is needed: Needed to keep this LDL-C marker question separate from the full original multi-lipid assessment.
Referenced methods: M03 §3.1, §3.2.1–3.2.4: question-clarification principles; detailed separation rules are locally designed; M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed — case-specific adaptation for the separate question.

N02 · Are eligibility criteria and baseline characteristics verified?

Required materials and conditions: The original article’s inclusion/exclusion criteria, age, baseline table and preceding dietary procedures.
Conditions for verification: Connect primary hypercholesterolaemia with LDL-C >160 mg/dL despite dietary management to actual eligibility and baseline characteristics.
Requirement and applicability: Required
Application exceptions: Distinguish the planned adult-population question from unverified age/comorbidity details; do not establish a failure of representativeness.
Why this condition is needed: Needed to avoid transferring results in a high-LDL population to all adults, CKD or add-on statin strategies.
Referenced methods: M03 §3.2.1: detailed population conditions are locally designed; M08 §8.1–8.2.3: local application — case-specific adaptation for population and selection.

N03 · Does this trial concern correction of B3 deficiency?

Required materials and conditions: Deficiency-based selection, baseline B3 concentrations and eligibility definitions.
Conditions for verification: Distinguish a trial not selected for deficiency from the limited scope of unreported B3 concentrations in the abstract/tables.
Requirement and applicability: Required (population boundary)
Application exceptions: Unreported B3 concentrations do not establish laboratory-confirmed absence of deficiency. Do not require concentration measurement unconditionally for the narrow lipid question.
Why this condition is needed: Needed to distinguish nutritional-deficiency treatment from lipid changes at pharmacological doses.
Referenced methods: M03 §3.2.1: detailed population conditions are locally designed; M03 §3.2.1–3.2.4: dose, duration and effect-modification details are locally designed — case-specific adaptation for nutritional status.

N04 · What are the selected ingredient, formulation and route?

Required materials and conditions: Original labelling and product identity for NIASPAN ingredient, ER formulation and oral route.
Conditions for verification: Distinguish oral NIASPAN nicotinic acid extended-release tablets from other B3 forms.
Requirement and applicability: Required
Application exceptions: Do not combine general vitamin B3, inositol hexanicotinate, nicotinamide or other formulations as direct evidence.
Why this condition is needed: Needed to avoid assigning the same effects/harms to other molecules or release formulations.
Referenced methods: M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed — case-specific adaptation for ingredient and formulation.

N05 · Are the target dose, titration and actual administration history verified?

Required materials and conditions: Arm-specific titration schedules, administration/stopping histories and actual doses.
Conditions for verification: Distinguish the target 2000 mg/day, 4-week titration and actual administration/adherence.
Requirement and applicability: Required
Application exceptions: The 1000 mg arm in the same trial is a supporting record; do not create a pooled mean dose.
Why this condition is needed: Needed to avoid treating the target 2000 mg as actual exposure throughout the entire period.
Referenced methods: M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed; M03 §3.2.3, M08 §8.2.2–8.2.3: local application — case-specific adaptation for dose and actual exposure.

N06 · What is the main comparator strategy?

Required materials and conditions: The common dietary treatment, placebo composition and contemporaneous Table 3 comparison.
Conditions for verification: Connect contemporaneous 2000 mg and placebo arms on the same dietary background.
Requirement and applicability: Required
Application exceptions: Do not substitute AIM-HIGH’s low-dose IR control or statin ± ezetimibe strategy for this placebo.
Why this condition is needed: The comparison must retain the same time/background to preserve attribution of the LDL-C difference.
Referenced methods: M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed; M03 §3.2.3, M08 §8.2.2–8.2.3: local application — case-specific adaptation for comparator strategy.

N07 · Is the linkage between abstract and regulatory-table periods/phases verified?

Required materials and conditions: Original article visit schedules, titration/maintenance phases and an FDA trial-family crosswalk.
Conditions for verification: Retain the label’s 16 weeks including 4-week titration and the abstract’s 12-week definition, with limits on exact phase linkage.
Requirement and applicability: Required
Application exceptions: The 16-week and 12-week definitions are not automatically conflicting data. Do not establish actual phase correspondence beyond the label.
Why this condition is needed: Needed to avoid automatically treating different duration labels as errors or replacing them with one value.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed; M03 §3.2.1–3.2.4: dose, duration and effect-modification details are locally designed; M04 §4.6.3, M15 §15.3.1–15.3.3: state separation is locally designed — case-specific adaptation for duration and phase linkage.

N08 · What are the selected outcome measure and unit?

Required materials and conditions: Table 3 mean percentage-change definition, units and baseline reference.
Conditions for verification: Connect mean LDL-C percentage change from baseline at 16 weeks with the percentage-point contrast, distinguishing concentration, medians and other lipids.
Requirement and applicability: Required
Application exceptions: Do not replace mean LDL-C change with Table 5 medians/IQR, Table 4 at other times or TG.
Why this condition is needed: Needed to avoid mixing results measured differently or at other times, even for the same lipid.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed; M08 Table 8.2.a, M03 §3.2.4: local application — case-specific adaptation for endpoint and unit.

N09 · Are the actual design, allocation and concealment implementation verified?

Required materials and conditions: Original methods for random sequence generation, allocation concealment and the baseline table.
Conditions for verification: Show both the abstract’s randomized double-blind fixed-dose placebo-controlled description and unverified allocation implementation.
Requirement and applicability: Required
Application exceptions: Do not invent unreported parallel/crossover details or equate unverified allocation concealment with confirmed failure.
Why this condition is needed: Needed to avoid treating an RCT label alone as resolving allocation and confounding issues.
Referenced methods: M08 §8.1–8.2.3: local application — case-specific adaptation for design and allocation.

N10 · Are maintenance of blinding and arm-specific assessment information verified?

Required materials and conditions: Participant, staff and assessor blinding procedures and assessments of maintained blinding.
Conditions for verification: Distinguish the double-blind description from actual maintenance/assessment procedures.
Requirement and applicability: Required
Application exceptions: Warnings about pharmacological-dose flushing alone do not establish unblinding.
Why this condition is needed: A double-blind label does not replace an actual assessment of maintained blinding.
Referenced methods: M08 §8.1–8.2.3: local application; M08 Table 8.2.a, M03 §3.2.4: local application — case-specific adaptation for maintenance of blinding.

N11 · Are individual co-treatment and dietary exposures verified?

Required materials and conditions: Arm-specific total diet, concomitant drugs/vitamins, rescue treatment and change histories.
Conditions for verification: Distinguish the common dietary background from actual differences in total diet and concurrent vitamins/treatment.
Requirement and applicability: Required
Application exceptions: A description that this is not a B-complex intervention does not establish absence of concurrent vitamins in individuals.
Why this condition is needed: A common treatment background does not establish identical individual exposures.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3: local application; M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed — case-specific adaptation for co-treatment and diet.

N12 · Are actual adherence and the analytical handling of treatment deviations verified?

Required materials and conditions: Arm-specific adherence, stopping/dose changes and handling rules.
Conditions for verification: Connect prescribed doses to actual adherence, changes, stopping and their handling.
Requirement and applicability: Required
Application exceptions: Unverified adherence details do not establish that the intervention was never administered.
Why this condition is needed: Needed to avoid filling missing actual exposure with 100% adherence or a PP analysis.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3: local application; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for adherence and treatment deviations.

N13 · Are the LDL-C assay and arm-specific measurement procedures verified?

Required materials and conditions: Original LDL-C assay, specimen/blood-sampling conditions and visit-specific measurement procedures.
Conditions for verification: Distinguish objective blood-lipid measurement from the actual assay, sampling/visits and measurement limitations.
Requirement and applicability: Required
Application exceptions: Do not delete observed values because the assay is unverified or assert that laboratory interference actually occurred.
Why this condition is needed: Describing an objective marker does not verify every measurement procedure.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4: local application; M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed — case-specific adaptation for measurement procedures.

N14 · What are the LDL-C values for the two arms at the same time in Table 3?

Required materials and conditions: FDA Table 3 arm-specific values/footnotes and the article’s 2000 mg LDL result.
Conditions for verification: Retain mean percentage changes of −14% and −1% with their respective arms, table and time.
Requirement and applicability: Required
Application exceptions: Do not promote an observed decrease to adequate precision, prevention of clinical events or an individual success probability.
Why this condition is needed: Favourable values must also retain their source attribution, without mixing values from other doses.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for arm-specific observations.

N15 · What does the retained −13 percentage-point value represent?

Required materials and conditions: Original difference, unit, method and prohibited-conversion records.
Conditions for verification: Record only the already-retained arithmetic contrast between arm-specific mean percentage changes; do not convert it to an adjusted effect, a new CI or concentration.
Requirement and applicability: Required
Application exceptions: Do not rerun the calculation or reconstruct mg/dL changes without baseline concentrations, ARR, NNT, SMD or CI.
Why this condition is needed: Needed to retain the meaning of existing arithmetic without generating a new effect calculation.
Referenced methods: M08 §8.2.2, M15 §15.3.1: local application; M15 §15.3.1–15.3.3: local application; M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed — case-specific adaptation for the historical contrast.

N16 · Are the analysis population and model for the LDL-C contrast verified?

Required materials and conditions: Article analysis populations, estimands, models, adjustment and table-specific analysis methods.
Conditions for verification: Link ITT/PP, adjustment and completer/assignment effects to original analyses; do not invent unknown analyses.
Requirement and applicability: Required
Application exceptions: Do not invent ITT/PP or adjusted values or use baseline n as actual analysis n.
Why this condition is needed: Needed to avoid establishing ITT or an adjusted causal difference from an arithmetic contrast alone.
Referenced methods: M08 §8.2.2, M15 §15.3.1: local application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed — case-specific adaptation for effect of interest and analysis.

N17 · Are denominators from allocation through analysis verified for each arm?

Required materials and conditions: Arm-specific recruitment, allocation, completion, analysis and dropout flow, and Table 3 analysis n.
Conditions for verification: Distinguish and connect the total 122, key baseline 41/40 and actual analysed/completed/dropout denominators.
Requirement and applicability: Required
Application exceptions: The total 122 includes a 1000 mg arm. The 41/40 values are baseline n, not verified complete analysis n.
Why this condition is needed: Needed to avoid automatically reusing the total 122 or baseline 41/40 as analysis denominators.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for allocation-to-analysis denominators.

N18 · Are the reasons for missing data/dropout and their handling verified?

Required materials and conditions: Arm-specific dropout reasons, missing LDL-C and imputation/sensitivity analyses.
Conditions for verification: Connect missing-data/dropout counts, reasons and handling to the selected analysis.
Requirement and applicability: Required
Application exceptions: Do not turn unavailable information into a high dropout rate or a quantified, established bias.
Why this condition is needed: Needed to avoid turning unknown dropout into 0 or an absence of bias.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for missing-data handling.

N19 · Are dispersion and the between-arm CI reported for LDL-C percentage change at the same time?

Required materials and conditions: Arm-specific percentage-change dispersion, analysis n, between-arm CI and derivation methods.
Conditions for verification: Verify SD/SE for the relevant percentage changes and the between-arm CI at the same denominator and time.
Requirement and applicability: Required
Application exceptions: A statement that selected original regulatory tables do not report a value must not be extended to all articles.
Why this condition is needed: Needed to avoid reconstructing precision from a significance threshold or an interval for another outcome.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed; M15 §15.3.1–15.3.3: local application — case-specific adaptation for dispersion and CI.

N20 · Are the exact P value and test definition verified?

Required materials and conditions: Table 3 testing footnotes, exact P and multiplicity/adjustment methods.
Conditions for verification: Distinguish the table threshold P<0.05 from exact P, testing/adjustment and CI.
Requirement and applicability: Required
Application exceptions: P<0.05 is not an exact P, CI or SD. Do not invent nonsignificant or equivalence results.
Why this condition is needed: Needed to avoid treating a significance threshold as adequate precision or effect size.
Referenced methods: M15 §15.3.1–15.3.3: local application; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for testing and significance.

N21 · Can the between-arm interval be interpreted against a justified important difference?

Required materials and conditions: The LDL-C contrast CI, evidence for an important difference in this question and interpretation limits.
Conditions for verification: Link the reported CI to evidence for an important difference in this question; do not turn EX(a) into effect0 or failure to reach an MCID.
Requirement and applicability: Required (precision interpretation)
Application exceptions: Do not create common sample-size, duration or trial-count thresholds or use the original C/46/EX cap as a numerical important-difference criterion.
Why this condition is needed: Needed to retain the observed lipid decrease without adding conclusions about sufficient effect or clinical benefit.
Referenced methods: M15 §15.3.1–15.3.3: local application; M03 §3.2.4: locally defined extension boundary — case-specific adaptation for important difference.

N22 · Do reported endpoints, times and analyses agree with the original plan?

Required materials and conditions: Initial registration, protocol, analysis plan and amendment history.
Conditions for verification: Verify only the portions actually compared between original registration/protocol/analysis plan and reported LDL-C results.
Requirement and applicability: Required
Application exceptions: An NCT value of null does not establish nonregistration. An unavailable plan is not definitive evidence of selective reporting.
Why this condition is needed: Needed to avoid establishing agreement with a registered 1st (primary) endpoint from the abstract/label alone.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3: local application; M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design — case-specific adaptation for plans and registration.

N23 · At what level are the article and label linked to the same trial family?

Required materials and conditions: Trial identifiers and population/arm/time crosswalks between the article and FDA trial tables.
Conditions for verification: Link matching design/n/dose in the article and regulatory table without inventing a patient-level crosswalk or 2 independent trials.
Requirement and applicability: Required
Application exceptions: The 2 bibliographic/regulatory reports are not 2 unique trials. Do not automatically merge other trial families in the full label into the same trial.
Why this condition is needed: Needed to avoid adding the article and FDA re-report as independent replications.
Referenced methods: M04 §4.6.1–4.6.2: distinction between studies and reports; cohort/outcome linkage is local application; M04 §4.6.1–4.6.2, M15 §15.3.1: local application — case-specific adaptation for reports and trial family.

N24 · Is independent replication of this question verified?

Required materials and conditions: Unique families, outcomes, funding and authorship for additional eligible trials.
Conditions for verification: Link unique studies with the same product/population/measure to independent author and funding information.
Requirement and applicability: Supplementary; required for replication claims
Application exceptions: Unavailable additional eligible material does not mean 0 studies worldwide or no effect.
Why this condition is needed: Needed to avoid automatically promoting multiple label trials or original R1 into an independent-replication count.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1: local application; M04 §4.6.1–4.6.2: distinction between studies and reports; cohort/outcome linkage is local application; Chamgap’s own independence/attribution condition. The official methodological sections used in this pilot do not guarantee all these details — case-specific adaptation for independent replication.

N25 · Are research funding, product provision and author interests verified?

Required materials and conditions: Complete original article funding, product provision, employment/patents and COI declarations.
Conditions for verification: Link actual full funding/COI declarations while retaining uncertainty about manufacturer-only or independent funding.
Requirement and applicability: Supplementary; required for independence claims
Application exceptions: Do not infer specific funding or the magnitude of bias from the NIASPAN product name or regulatory table alone.
Why this condition is needed: Needed to avoid converting unavailable full text into certainty of manufacturer-only or independent research.
Referenced methods: Chamgap’s own independence/attribution condition. The official methodological sections used in this pilot do not guarantee all these details — case-specific adaptation for funding and COI.

N26 · Are the causes of inconsistent reports for other doses/endpoints verified?

Required materials and conditions: Relevant original publisher-abstract/regulatory-table data, phases/denominators and corrections for 1000 mg LDL, TG and related values.
Conditions for verification: Retain the agreeing 2000 mg LDL value and mark the causes of actual inconsistencies for other doses/endpoints as unverified.
Requirement and applicability: Required
Application exceptions: A different dose alone is not automatically conflicting data. Retain only inconsistencies explicit in the current record; do not invent causes or new values.
Why this condition is needed: Needed to avoid erasing related inconsistencies because some values agree or arbitrarily correcting them as rounding.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3: state separation is locally designed; M04 §4.6.1–4.6.2, M15 §15.3.1: local application — case-specific adaptation for inconsistent reports.

N27 · Does LDL-C change answer whether myocardial infarction or mortality is prevented?

Required materials and conditions: Direct event studies with the same strategy/population if extending to events or mortality.
Conditions for verification: Separate the lipid-change question from event/mortality questions.
Requirement and applicability: Supplementary; required for clinical-event extensions
Application exceptions: Do not require an event trial for the narrow LDL-C percentage-change question. This table does not assess event prevention.
Why this condition is needed: Needed to avoid automatically converting surrogate improvement into prevention of clinical events.
Referenced methods: M03 §3.2.4: locally defined extension boundary — case-specific adaptation for extension to clinical events.

N28 · Does the result answer questions about optimal dose, long-term maintenance or specific subgroups?

Required materials and conditions: Direct dose comparisons, long-term follow-up and prespecified subgroup/interaction data if extending the claim.
Conditions for verification: Do not extend the fixed-comparison 16-week result to optimal dose, long-term persistence or effect modification.
Requirement and applicability: Supplementary; required for the relevant extension
Application exceptions: The presence of a 1000 mg arm does not establish an optimal dose. Do not require every long-term/subgroup study for the narrow 16-week question.
Why this condition is needed: Needed to avoid transferring one key dose/period to optimization or maintenance effects.
Referenced methods: M03 §3.2.1–3.2.4: dose, duration and effect-modification details are locally designed — case-specific adaptation for dose and long-term extensions.

N29 · Are arm-specific harm collection, event/person counts and stopping denominators verified for the key trial?

Required materials and conditions: The key trial’s AE definitions, collection, people/events, stopping, exposure time and arm-specific denominators.
Conditions for verification: Separate original warnings from actual arm-specific harm counts in the key small trial; do not use pooled data as trial event rates.
Requirement and applicability: Supplementary; required for harm/safety claims
Application exceptions: Do not use FDA2020 pooled safety data as event rates in this trial or convert unverified harms into harmlessness or AE0.
Why this condition is needed: The presence of efficacy data or regulatory warnings does not establish complete harm counts in the same trial.
Referenced methods: M19 §19.1.2–19.2.4: local application; M19 §19.1.2–19.2.4: detailed distinctions are locally designed; M19 §19.1.2–19.2.4, M04 §4.6.3: local application — case-specific adaptation for harm collection and denominators.

N30 · Are temporal order, co-treatment and alternative comparative causes verified for harms in the selected trial?

Required materials and conditions: Trial AE onset, stopping/recovery, concurrent medication/baseline disease, comparisons and long-term vulnerable-group data.
Conditions for verification: Link warnings to actual timing, comparisons and alternatives in the same population/exposure, without converting a signal to a causal rate.
Requirement and applicability: Supplementary; required for harm causality/scope
Application exceptions: Do not invent rechallenge, recovery, incidence or rare long-term-risk values from a summary without event counts. No H07 independent replicated-harm claim is made in this work.
Why this condition is needed: Needed to avoid automatically extending label warnings to causal risk estimates or overall safety in the selected trial.
Referenced methods: M19 §19.1.2–19.2.4: local application; M19 §19.2: design-specific harm questions, with locally designed temporal details; M19 §19.2.2–19.2.4, M03 §3.2.3: local application; M19 §19.2.2–19.2.4: design considerations, with locally designed confounding records; Chamgap’s own interpretive boundary. M19 principles inform this work; no official causality tool was executed — case-specific adaptation for harm timing and alternatives.

N31 · Within what scope was reported laboratory interference verified?

Required materials and conditions: FDA7.6 assay-specific interference conditions and the original trial LDL-C assay/interference observations.
Conditions for verification: Do not convert original assay-specific warnings into actual LDL-C measurement errors or effects on all tests.
Requirement and applicability: Supplementary; required for interference claims
Application exceptions: Do not add test names, mechanisms or frequencies absent from the original inputs or assert that LDL-C interference occurred.
Why this condition is needed: Needed to avoid extending label interference warnings to invalidation of this trial’s LDL-C effect or interference with all tests.
Referenced methods: M19 §19.1.2–19.2.4: local application; M19 §19.1.2–19.2.4: detailed distinctions are locally designed; Chamgap’s own interpretive boundary. M19 principles inform this work; no official causality tool was executed; M08 Table 8.2.a, M03 §3.2.4: local application — case-specific adaptation for laboratory interference.

N32 · Which material was actually read in this work?

Required materials and conditions: Current input SHA, material type/URL, historical access locations, individual access dates and global review date.
Conditions for verification: Distinguish original-byte retained summaries, historical access in original citations and current external access not attempted/unread for each material.
Requirement and applicability: Required
Application exceptions: Citations have no individual access dates. Do not infer that the 2026-09-14 review date was an actual access date or automatically inherit report access for the DOI entry.
Why this condition is needed: Needed to avoid converting reading of the retained summary into current reading of FDA PDFs, articles or DOI-linked full texts.
Referenced methods: M04 §4.5–4.6: material-collection/selection principles; access/reading separation and the hyperlink contract are locally designed; M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design — case-specific adaptation for material reading.

N33 · What search, correction and history scope is retained?

Required materials and conditions: Existing search records, 5 corrections, inputs used and the unpublished/registration verification scope.
Conditions for verification: Distinguish the 2026-09-14 web indexing/existing searches/corrections from this local conversion.
Requirement and applicability: Required
Application exceptions: Separate original verification reports, source lists and shared correction records were not opened in this work; S17/S19 without citations are not made into new reports.
Why this condition is needed: Needed to avoid promoting old internal validation/web indexing to a current exhaustive clinical search.
Referenced methods: M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design; M04 §4.6.3, M15 §15.3.1–15.3.3: state separation is locally designed; M08 Table 8.2.a, M04 §4.6.3: local application — case-specific adaptation for verification scope and history.

N34 · How are original assessments/numbers distinguished from table-review status?

Required materials and conditions: Original grade/score/axes, calculation records, gaps, corrections and original internal-review metadata.
Conditions for verification: Retain C46, original axes/EX/CX, original caution, nulls and historical arithmetic; table-preparation verification is not efficacy/safety certification.
Requirement and applicability: Required (display boundary)
Application exceptions: Original document-quality A and internal validation are distinct from evidence C/46. Table preparation, another author’s QA, technical/UI checks and publication are also separate statuses.
Why this condition is needed: Needed to avoid interpreting blue verification in the table as a new clinical-efficacy grade, fulfilment percentage or official certification.
Referenced methods: M03 §3.1, §3.2.1–3.2.4: question-clarification principles; detailed separation rules are locally designed; M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design; M15 §15.3.1–15.3.3: local application; Chamgap’s own interpretive boundary. M19 principles inform this work; no official causality tool was executed — case-specific adaptation for original assessment and table status.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes; distinguish intervention variants.
Extent of review: Retained methodological-application records were reused. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish and link studies and reports; do not omit studies solely because outcomes are unreported.
Extent of review: Retained methodological-application records were reused. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Fix the outcome and effect of interest, then review randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Retained methodological-application records were reused. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effects, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Retained methodological-application records were reused. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require designs, populations and follow-up different from efficacy questions. Case reports do not establish incidence.
Extent of review: Retained methodological-application records were reused. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Met: Identity, attribution and scope for this condition are verified in retained material, separately from clinical sufficiency/certification.
Partly verified: Some information is verified; actual methods, denominators or procedures remain unresolved.
Unverified: Required clinical data/values are unverified within this reading scope. This does not mean effect0, harmlessness or unfinished table preparation.
Conflicting data: Inconsistent reports in original records, distinct from differences in dose/time alone.
Not applicable: An extension requirement outside the narrow lipid question is inapplicable; not a substitute for unread material.
Not applicable (spaced alias): Grey alias for Not applicable.
Unread: External originals were not directly read in this work, distinct from reading retained summaries.
Review incomplete: A label for unfinished item-specific table review. This case’s retained-record review is complete, separately from unverified clinical data and unread external originals.

Change history

2026-10-29 · Public page/material version 1.0

Prepared a public reader and materials from the existing 34 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (2026-10-05) and original evidence review date (2026-09-14) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which NIASPAN LDL-C contrast is retained?

Current findings: The assessed claim is mean LDL-C percentage change in primary hypercholesterolaemia, limited to oral NIASPAN nicotinic acid extended-release tablets at 2000 mg/day versus diet plus placebo over 16 weeks including titration.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The exact assessed claim, claim conditions and editorial scope support this single question.
Reason for missing information: The earlier review verified this claim identity and scope in retained material and recorded that new checking of external originals and website publication had not been performed at that time.
Required materials and conditions: Exact locations for the assessed claim, claim conditions and editorial scope, and the canonical URL.
Materials to obtain first: Exact locations for the assessed claim, claim conditions and editorial scope, and the canonical URL.
Further research: First fix the question and report-eligibility table, then check whether other formulations, TG or clinical-event questions have entered the scope.
Remaining uncertainty: The earlier review verified this claim identity and scope in retained material and recorded that new checking of external originals and website publication had not been performed at that time.
Conditions for verification: Connect the exact assessed claim, formulation, population, diet plus placebo, 2000 mg/day and 16 weeks including titration as one question.
Why this condition is needed: Needed to keep this LDL-C marker question separate from the full original multi-lipid assessment.
Application exceptions: The subclaim array is empty. Do not automatically generate tables for other doses/endpoints or rewrite 128/2346.
Referenced methods: M03 §3.1, §3.2.1–3.2.4: question-clarification principles; detailed separation rules are locally designed; M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed — case-specific adaptation for the separate question.

Related sources S15 S16

N02 · Are eligibility criteria and baseline characteristics verified?

Current findings: The population has primary hypercholesterolaemia with LDL-C >160 mg/dL despite dietary management. Retained summaries distinguish this from deficiency correction and add-on statin strategies, but the retained abstract/regulatory-table summaries do not verify detailed eligibility or baseline tables.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The diagnosis and LDL entry criterion are stated; detailed recruitment and baseline composition remain unresolved.
Reason for missing information: Detailed age, comorbidities, eligibility and baseline balance between arms are unverified.
Required materials and conditions: The original article’s inclusion/exclusion criteria, age, baseline table and preceding dietary procedures.
Materials to obtain first: The original article’s inclusion/exclusion criteria, age, baseline table and preceding dietary procedures.
Further research: Check recruitment criteria and baseline tables against the target and included populations, including selection limitations.
Remaining uncertainty: Detailed age, comorbidities, eligibility and baseline balance between arms are unverified.
Conditions for verification: Connect primary hypercholesterolaemia with LDL-C >160 mg/dL despite dietary management to actual eligibility and baseline characteristics.
Why this condition is needed: Needed to avoid transferring results in a high-LDL population to all adults, CKD or add-on statin strategies.
Application exceptions: Distinguish the planned adult-population question from unverified age/comorbidity details; do not establish a failure of representativeness.
Referenced methods: M03 §3.2.1: detailed population conditions are locally designed; M08 §8.1–8.2.3: local application — case-specific adaptation for population and selection.

Related sources S15 S16

N03 · Does this trial concern correction of B3 deficiency?

Current findings: The retained record states that the trial did not select nutritional deficiency and that the abstract/tables used contained no diagnostic B3 concentration data.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The non-deficiency selection boundary and the limited concentration-reporting scope were verified.
Reason for missing information: The scope was verified as a trial not selected for deficiency. Individual B3 deficiency status and baseline concentrations were not verified.
Required materials and conditions: Deficiency-based selection, baseline B3 concentrations and eligibility definitions.
Materials to obtain first: Deficiency-based selection, baseline B3 concentrations and eligibility definitions.
Further research: Check whether original recruitment criteria required deficiency; do not pool deficiency-correction evidence as a high-LDL treatment effect.
Remaining uncertainty: The scope was verified as a trial not selected for deficiency. Individual B3 deficiency status and baseline concentrations were not verified.
Conditions for verification: Distinguish a trial not selected for deficiency from the limited scope of unreported B3 concentrations in the abstract/tables.
Why this condition is needed: Needed to distinguish nutritional-deficiency treatment from lipid changes at pharmacological doses.
Application exceptions: Unreported B3 concentrations do not establish laboratory-confirmed absence of deficiency. Do not require concentration measurement unconditionally for the narrow lipid question.
Referenced methods: M03 §3.2.1: detailed population conditions are locally designed; M03 §3.2.1–3.2.4: dose, duration and effect-modification details are locally designed — case-specific adaptation for nutritional status.

Related sources S15 S16

N04 · What are the selected ingredient, formulation and route?

Current findings: The original records identify oral NIASPAN nicotinic acid extended-release and record that other niacin forms are not equivalent.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: Retained ingredient, formulation and route identities agree.
Reason for missing information: This product/route boundary was verified. Current physical labelling, product approval and manufacturing origin were not newly verified.
Required materials and conditions: Original labelling and product identity for NIASPAN ingredient, ER formulation and oral route.
Materials to obtain first: Original labelling and product identity for NIASPAN ingredient, ER formulation and oral route.
Further research: Link product/formulation definitions to result tables and exclude interchange at the same mg dose with immediate-release, sustained-release, no-flush products or nicotinamide.
Remaining uncertainty: This product/route boundary was verified. Current physical labelling, product approval and manufacturing origin were not newly verified.
Conditions for verification: Distinguish oral NIASPAN nicotinic acid extended-release tablets from other B3 forms.
Why this condition is needed: Needed to avoid assigning the same effects/harms to other molecules or release formulations.
Application exceptions: Do not combine general vitamin B3, inositol hexanicotinate, nicotinamide or other formulations as direct evidence.
Referenced methods: M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed — case-specific adaptation for ingredient and formulation.

Related sources S15 S16

N05 · Are the target dose, titration and actual administration history verified?

Current findings: The key contrast is 2000 mg/day and the label period includes 4-week titration. A 1000 mg arm is also present, but detailed titration and administration histories are unconfirmed.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The target dose and titration-inclusive definition were verified; detailed actual exposure is unavailable.
Reason for missing information: Doses at each titration visit, adherence and actual cumulative exposure are unverified.
Required materials and conditions: Arm-specific titration schedules, administration/stopping histories and actual doses.
Materials to obtain first: Arm-specific titration schedules, administration/stopping histories and actual doses.
Further research: Reconstruct exposure during titration and maintenance, then compare actual doses and deviations with intended prescribing.
Remaining uncertainty: Doses at each titration visit, adherence and actual cumulative exposure are unverified.
Conditions for verification: Distinguish the target 2000 mg/day, 4-week titration and actual administration/adherence.
Why this condition is needed: Needed to avoid treating the target 2000 mg as actual exposure throughout the entire period.
Application exceptions: The 1000 mg arm in the same trial is a supporting record; do not create a pooled mean dose.
Referenced methods: M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed; M03 §3.2.3, M08 §8.2.2–8.2.3: local application — case-specific adaptation for dose and actual exposure.

Related sources S15 S16

N06 · What is the main comparator strategy?

Current findings: The selected comparator is matched placebo on the same dietary-treatment background. Use the contemporaneous fixed-dose comparison in Table 3, without mixing the dose-escalation table at other times.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The comparator conditions and the current article/regulatory-table comparison scope are explicit.
Reason for missing information: The main comparator strategy was verified. Detailed dietary adherence and individual co-treatment differences remain separately unverified.
Required materials and conditions: The common dietary treatment, placebo composition and contemporaneous Table 3 comparison.
Materials to obtain first: The common dietary treatment, placebo composition and contemporaneous Table 3 comparison.
Further research: Compare intervention/control strategies and exclude add-on statin TG strategies and other times in the dose-escalation table.
Remaining uncertainty: The main comparator strategy was verified. Detailed dietary adherence and individual co-treatment differences remain separately unverified.
Conditions for verification: Connect contemporaneous 2000 mg and placebo arms on the same dietary background.
Why this condition is needed: The comparison must retain the same time/background to preserve attribution of the LDL-C difference.
Application exceptions: Do not substitute AIM-HIGH’s low-dose IR control or statin ± ezetimibe strategy for this placebo.
Referenced methods: M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed; M03 §3.2.3, M08 §8.2.2–8.2.3: local application — case-specific adaptation for comparator strategy.

Related sources S15 S16

N07 · Is the linkage between abstract and regulatory-table periods/phases verified?

Current findings: FDA Table 3 covers 16 weeks including 4-week titration; the publisher abstract describes 12 weeks of treatment. The original citation does not assert exact phase linkage beyond the label definition.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: Both source definitions are explicit, but detailed phase linkage is unconfirmed.
Reason for missing information: Article visit durations and phase-specific participant/analysis correspondence in the label are unverified.
Required materials and conditions: Original article visit schedules, titration/maintenance phases and an FDA trial-family crosswalk.
Materials to obtain first: Original article visit schedules, titration/maintenance phases and an FDA trial-family crosswalk.
Further research: Compare timelines and visit schedules side by side to verify phase linkage; do not arbitrarily adjust different durations.
Remaining uncertainty: Article visit durations and phase-specific participant/analysis correspondence in the label are unverified.
Conditions for verification: Retain the label’s 16 weeks including 4-week titration and the abstract’s 12-week definition, with limits on exact phase linkage.
Why this condition is needed: Needed to avoid automatically treating different duration labels as errors or replacing them with one value.
Application exceptions: The 16-week and 12-week definitions are not automatically conflicting data. Do not establish actual phase correspondence beyond the label.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed; M03 §3.2.1–3.2.4: dose, duration and effect-modification details are locally designed; M04 §4.6.3, M15 §15.3.1–15.3.3: state separation is locally designed — case-specific adaptation for duration and phase linkage.

Related sources S15 S16

N08 · What are the selected outcome measure and unit?

Current findings: The selected endpoint is mean LDL-C percentage change from baseline at 16 weeks in FDA Table 3. Arm values are percentages; the original arithmetic between-arm contrast is in percentage points.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The endpoint, mean percentage change and units are explicit in the original calculation record and claim conditions.
Reason for missing information: This measure/unit was verified. Changes in mg/dL, other times or medians were not substituted as verified primary effects.
Required materials and conditions: Table 3 mean percentage-change definition, units and baseline reference.
Materials to obtain first: Table 3 mean percentage-change definition, units and baseline reference.
Further research: Check table headings, footnotes and measures against original material; record differences between means/medians and concentration/%/percentage points.
Remaining uncertainty: This measure/unit was verified. Changes in mg/dL, other times or medians were not substituted as verified primary effects.
Conditions for verification: Connect mean LDL-C percentage change from baseline at 16 weeks with the percentage-point contrast, distinguishing concentration, medians and other lipids.
Why this condition is needed: Needed to avoid mixing results measured differently or at other times, even for the same lipid.
Application exceptions: Do not replace mean LDL-C change with Table 5 medians/IQR, Table 4 at other times or TG.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed; M08 Table 8.2.a, M03 §3.2.4: local application — case-specific adaptation for endpoint and unit.

Related sources S15 S16

N09 · Are the actual design, allocation and concealment implementation verified?

Current findings: The S16 abstract describes a randomized double-blind fixed-dose placebo-controlled design. Allocation-concealment implementation remains unverified without the article full text.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The design description is verified; implementation details remain unresolved.
Reason for missing information: Random sequence generation, allocation concealment and baseline-balance details are unverified.
Required materials and conditions: Original methods for random sequence generation, allocation concealment and the baseline table.
Materials to obtain first: Original methods for random sequence generation, allocation concealment and the baseline table.
Further research: Compare sequence generation, enrolment/allocation procedures and concealment implementation with original methods, separating design labels from implementation verification.
Remaining uncertainty: Random sequence generation, allocation concealment and baseline-balance details are unverified.
Conditions for verification: Show both the abstract’s randomized double-blind fixed-dose placebo-controlled description and unverified allocation implementation.
Why this condition is needed: Needed to avoid treating an RCT label alone as resolving allocation and confounding issues.
Application exceptions: Do not invent unreported parallel/crossover details or equate unverified allocation concealment with confirmed failure.
Referenced methods: M08 §8.1–8.2.3: local application — case-specific adaptation for design and allocation.

Related sources S16

N10 · Are maintenance of blinding and arm-specific assessment information verified?

Current findings: The abstract confirms a double-blind design, but checks of maintained blinding remain unverified without full text. Flushing warnings are not converted into evidence of actual blinding failure.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The retained scope lacks the required actual blinding checks/assessment procedures.
Reason for missing information: Actual information about maintained blinding, assessor knowledge and arm-specific testing procedures is unverified.
Required materials and conditions: Participant, staff and assessor blinding procedures and assessments of maintained blinding.
Materials to obtain first: Participant, staff and assessor blinding procedures and assessments of maintained blinding.
Further research: Compare who was blinded, blinding checks and assessor knowledge with original methods, considering limitations for objective lipid outcomes.
Remaining uncertainty: Actual information about maintained blinding, assessor knowledge and arm-specific testing procedures is unverified.
Conditions for verification: Distinguish the double-blind description from actual maintenance/assessment procedures.
Why this condition is needed: A double-blind label does not replace an actual assessment of maintained blinding.
Application exceptions: Warnings about pharmacological-dose flushing alone do not establish unblinding.
Referenced methods: M08 §8.1–8.2.3: local application; M08 Table 8.2.a, M03 §3.2.4: local application — case-specific adaptation for maintenance of blinding.

Related sources S15 S16

N11 · Are individual co-treatment and dietary exposures verified?

Current findings: The dietary-treatment background and 2000 mg/day study drug are verified, but total diet and individual concurrent vitamin use are unconfirmed.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The common treatment scope was verified; actual individual exposures remain unresolved.
Reason for missing information: Total diet, co-treatment, rescue treatment, arm-specific changes and their handling are unverified.
Required materials and conditions: Arm-specific total diet, concomitant drugs/vitamins, rescue treatment and change histories.
Materials to obtain first: Arm-specific total diet, concomitant drugs/vitamins, rescue treatment and change histories.
Further research: Extract co-treatment and dietary records by arm and review their handling in intervention strategies and selected analyses.
Remaining uncertainty: Total diet, co-treatment, rescue treatment, arm-specific changes and their handling are unverified.
Conditions for verification: Distinguish the common dietary background from actual differences in total diet and concurrent vitamins/treatment.
Why this condition is needed: A common treatment background does not establish identical individual exposures.
Application exceptions: A description that this is not a B-complex intervention does not establish absence of concurrent vitamins in individuals.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3: local application; M03 §3.2.2–3.2.3: reverse labelling and laboratory adaptations are locally designed — case-specific adaptation for co-treatment and diet.

Related sources S15 S16

N12 · Are actual adherence and the analytical handling of treatment deviations verified?

Current findings: The original assessment verified trial dose and dietary comparator but left detailed actual adherence unconfirmed.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: Arm-specific adherence, treatment changes and analytical handling records were not acquired.
Reason for missing information: Actual adherence, stopping/changes and their effects on analysis are unverified.
Required materials and conditions: Arm-specific adherence, stopping/dose changes and handling rules.
Materials to obtain first: Arm-specific adherence, stopping/dose changes and handling rules.
Further research: Link adherence/stopping tables to actual analysis populations and review differences between assignment-effect and adherence-effect interpretations.
Remaining uncertainty: Actual adherence, stopping/changes and their effects on analysis are unverified.
Conditions for verification: Connect prescribed doses to actual adherence, changes, stopping and their handling.
Why this condition is needed: Needed to avoid filling missing actual exposure with 100% adherence or a PP analysis.
Application exceptions: Unverified adherence details do not establish that the intervention was never administered.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3: local application; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for adherence and treatment deviations.

Related sources S16

N13 · Are the LDL-C assay and arm-specific measurement procedures verified?

Current findings: The original assessment describes objective blood-lipid markers. The retained summary read in this work does not verify detailed assays or specimen/sampling conditions.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The measurement target is verified; procedural details remain unresolved.
Reason for missing information: The LDL-C assay, sampling conditions, measurers and arm-specific visit procedures are unverified.
Required materials and conditions: Original LDL-C assay, specimen/blood-sampling conditions and visit-specific measurement procedures.
Materials to obtain first: Original LDL-C assay, specimen/blood-sampling conditions and visit-specific measurement procedures.
Further research: Link the assay and sampling/visit schedules to result tables and review arm-specific differences in methods and timing.
Remaining uncertainty: The LDL-C assay, sampling conditions, measurers and arm-specific visit procedures are unverified.
Conditions for verification: Distinguish objective blood-lipid measurement from the actual assay, sampling/visits and measurement limitations.
Why this condition is needed: Describing an objective marker does not verify every measurement procedure.
Application exceptions: Do not delete observed values because the assay is unverified or assert that laboratory interference actually occurred.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4: local application; M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed — case-specific adaptation for measurement procedures.

Related sources S15 S16

N14 · What are the LDL-C values for the two arms at the same time in Table 3?

Current findings: Original Table 3 reports mean percentage changes of −14% in the 2000 mg arm and −1% with placebo. The article abstract agrees at −14% for 2000 mg LDL-C.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The same arm-specific observations are retained in the current text and original calculation record.
Reason for missing information: These reported arm values and their attribution were verified. A new check of the physical original table, exact analysis n and CI was not performed.
Required materials and conditions: FDA Table 3 arm-specific values/footnotes and the article’s 2000 mg LDL result.
Materials to obtain first: FDA Table 3 arm-specific values/footnotes and the article’s 2000 mg LDL result.
Further research: Re-extract the agreeing 2000 mg LDL values against the original table/abstract’s arm, endpoint and period definitions.
Remaining uncertainty: These reported arm values and their attribution were verified. A new check of the physical original table, exact analysis n and CI was not performed.
Conditions for verification: Retain mean percentage changes of −14% and −1% with their respective arms, table and time.
Why this condition is needed: Favourable values must also retain their source attribution, without mixing values from other doses.
Application exceptions: Do not promote an observed decrease to adequate precision, prevention of clinical events or an individual success probability.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for arm-specific observations.

Related sources S15 S16

N15 · What does the retained −13 percentage-point value represent?

Current findings: −13 percentage points is the arithmetic contrast between −14% and −1% in the original ChatGPT calculation record. Its status is verification of the existing between-arm arithmetic contrast only; SE, SD, degrees of freedom and CI are null.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The original arithmetic-only definition and prohibited conversions are directly connected.
Reason for missing information: Only the existing descriptive arithmetic contrast was verified. An adjusted causal mean difference, CI, SMD, ARR and NNT remain unverified; no new calculation was performed.
Required materials and conditions: Original difference, unit, method and prohibited-conversion records.
Materials to obtain first: Original difference, unit, method and prohibited-conversion records.
Further research: Check the source, common time and direction of the retained arithmetic and whether wording transfers it to an adjusted estimate or clinical risk.
Remaining uncertainty: Only the existing descriptive arithmetic contrast was verified. An adjusted causal mean difference, CI, SMD, ARR and NNT remain unverified; no new calculation was performed.
Conditions for verification: Record only the already-retained arithmetic contrast between arm-specific mean percentage changes; do not convert it to an adjusted effect, a new CI or concentration.
Why this condition is needed: Needed to retain the meaning of existing arithmetic without generating a new effect calculation.
Application exceptions: Do not rerun the calculation or reconstruct mg/dL changes without baseline concentrations, ARR, NNT, SMD or CI.
Referenced methods: M08 §8.2.2, M15 §15.3.1: local application; M15 §15.3.1–15.3.3: local application; M03 §3.2.4, M15 §15.3.1–15.3.3: question-specific outcome adaptations are locally designed — case-specific adaptation for the historical contrast.

Related sources S15 S16

N16 · Are the analysis population and model for the LDL-C contrast verified?

Current findings: The original records verified only the arithmetic contrast; exact analysed, completed and dropout n and missing-data methods were unconfirmed. Conversion to an adjusted causal difference is also prohibited.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The original article full text needed to verify exact analysis methods, populations and models is currently unavailable in the retained material.
Reason for missing information: ITT/PP, analysis populations, adjustment, estimands and models are unverified.
Required materials and conditions: Article analysis populations, estimands, models, adjustment and table-specific analysis methods.
Materials to obtain first: Article analysis populations, estimands, models, adjustment and table-specific analysis methods.
Further research: Link methods and participants to arm-specific result tables and compare with the effect of interest and missing-data/deviation handling.
Remaining uncertainty: ITT/PP, analysis populations, adjustment, estimands and models are unverified.
Conditions for verification: Link ITT/PP, adjustment and completer/assignment effects to original analyses; do not invent unknown analyses.
Why this condition is needed: Needed to avoid establishing ITT or an adjusted causal difference from an arithmetic contrast alone.
Application exceptions: Do not invent ITT/PP or adjusted values or use baseline n as actual analysis n.
Referenced methods: M08 §8.2.2, M15 §15.3.1: local application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed — case-specific adaptation for effect of interest and analysis.

Related sources S15 S16

N17 · Are denominators from allocation through analysis verified for each arm?

Current findings: The trial total of 122 includes a 1000 mg arm; baseline n for the main contrast is 41 versus 40. The original sample-size role is baseline n, with completed/analysed sample sizes unverified.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: Total and baseline denominators are verified; outcome-specific analysis flow remains unresolved.
Reason for missing information: Exact analysed, completed and dropout n for each arm and denominators at the Table 3 time point are unverified.
Required materials and conditions: Arm-specific recruitment, allocation, completion, analysis and dropout flow, and Table 3 analysis n.
Materials to obtain first: Arm-specific recruitment, allocation, completion, analysis and dropout flow, and Table 3 analysis n.
Further research: Reconstruct each arm’s participant flow over time and verify correspondence between total/baseline samples and outcome-specific analysis denominators.
Remaining uncertainty: Exact analysed, completed and dropout n for each arm and denominators at the Table 3 time point are unverified.
Conditions for verification: Distinguish and connect the total 122, key baseline 41/40 and actual analysed/completed/dropout denominators.
Why this condition is needed: Needed to avoid automatically reusing the total 122 or baseline 41/40 as analysis denominators.
Application exceptions: The total 122 includes a 1000 mg arm. The 41/40 values are baseline n, not verified complete analysis n.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for allocation-to-analysis denominators.

Related sources S15 S16

N18 · Are the reasons for missing data/dropout and their handling verified?

Current findings: The original assessment’s missing-data and unresolved-issue records state that exact analysed, completed and dropout n and missing-data methods remain unconfirmed because the full text was not accessed.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The retained scope lacks the required loss/handling data.
Reason for missing information: Arm-specific dropout counts, reasons, missing-data handling and sensitivity results are unverified.
Required materials and conditions: Arm-specific dropout reasons, missing LDL-C and imputation/sensitivity analyses.
Materials to obtain first: Arm-specific dropout reasons, missing LDL-C and imputation/sensitivity analyses.
Further research: Compare missing-data tables with analysis methods and review whether results under alternative assumptions are available.
Remaining uncertainty: Arm-specific dropout counts, reasons, missing-data handling and sensitivity results are unverified.
Conditions for verification: Connect missing-data/dropout counts, reasons and handling to the selected analysis.
Why this condition is needed: Needed to avoid turning unknown dropout into 0 or an absence of bias.
Application exceptions: Do not turn unavailable information into a high dropout rate or a quantified, established bias.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for missing-data handling.

Related sources S16

N19 · Are dispersion and the between-arm CI reported for LDL-C percentage change at the same time?

Current findings: Standard error, change-score standard deviation, degrees of freedom, confidence level and interval are null. The retained record states that selected regulatory tables do not provide corresponding percentage-change dispersion or a lipid-contrast CI; Table 5 IQR and cardiovascular HR CIs were not substituted.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: Dispersion and CI for the same analysis were not acquired within the selected regulatory-table/abstract scope.
Reason for missing information: SD/SE, analysis n, CI and exact derivation methods for the selected lipid contrast are unverified.
Required materials and conditions: Arm-specific percentage-change dispersion, analysis n, between-arm CI and derivation methods.
Materials to obtain first: Arm-specific percentage-change dispersion, analysis n, between-arm CI and derivation methods.
Further research: Directly verify dispersion/intervals for the relevant analysis and check for substitution of another table’s IQR or a cardiovascular HR CI.
Remaining uncertainty: SD/SE, analysis n, CI and exact derivation methods for the selected lipid contrast are unverified.
Conditions for verification: Verify SD/SE for the relevant percentage changes and the between-arm CI at the same denominator and time.
Why this condition is needed: Needed to avoid reconstructing precision from a significance threshold or an interval for another outcome.
Application exceptions: A statement that selected original regulatory tables do not report a value must not be extended to all articles.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4: design-specific adaptations are locally designed; M15 §15.3.1–15.3.3: local application — case-specific adaptation for dispersion and CI.

Related sources S15 S16

N20 · Are the exact P value and test definition verified?

Current findings: The original product information explicitly states that the table’s P<0.05 is not an exact P, CI or SD. Testing/adjustment details remain unverified in the current material.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The reported threshold is retained; exact testing/adjustment remains unresolved.
Reason for missing information: Exact P, test type, multiplicity/adjustment and analysis denominators are unverified.
Required materials and conditions: Table 3 testing footnotes, exact P and multiplicity/adjustment methods.
Materials to obtain first: Table 3 testing footnotes, exact P and multiplicity/adjustment methods.
Further research: Verify test definitions, analysis populations and comparisons subject to adjustment; do not calculate CI/dispersion from the threshold.
Remaining uncertainty: Exact P, test type, multiplicity/adjustment and analysis denominators are unverified.
Conditions for verification: Distinguish the table threshold P<0.05 from exact P, testing/adjustment and CI.
Why this condition is needed: Needed to avoid treating a significance threshold as adequate precision or effect size.
Application exceptions: P<0.05 is not an exact P, CI or SD. Do not invent nonsignificant or equivalence results.
Referenced methods: M15 §15.3.1–15.3.3: local application; M08 §8.2.2, M15 §15.3.1: local application — case-specific adaptation for testing and significance.

Related sources S15

N21 · Can the between-arm interval be interpreted against a justified important difference?

Current findings: The original imprecision assessment retains unconfirmed lipid between-arm CI/SD and EX(a), without converting them to E0 or failure to reach an MCID. Established clinical benefit is not overstated.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The current material lacks a verified CI for this contrast and a justified important-difference criterion.
Reason for missing information: The effect range and its relationship to an important difference are unverified. The observed decrease itself was not converted to 0.
Required materials and conditions: The LDL-C contrast CI, evidence for an important difference in this question and interpretation limits.
Materials to obtain first: The LDL-C contrast CI, evidence for an important difference in this question and interpretation limits.
Further research: Review whether a justified important difference and the relevant interval are provided; otherwise, do not judge sufficiency from significance alone.
Remaining uncertainty: The effect range and its relationship to an important difference are unverified. The observed decrease itself was not converted to 0.
Conditions for verification: Link the reported CI to evidence for an important difference in this question; do not turn EX(a) into effect0 or failure to reach an MCID.
Why this condition is needed: Needed to retain the observed lipid decrease without adding conclusions about sufficient effect or clinical benefit.
Application exceptions: Do not create common sample-size, duration or trial-count thresholds or use the original C/46/EX cap as a numerical important-difference criterion.
Referenced methods: M15 §15.3.1–15.3.3: local application; M03 §3.2.4: locally defined extension boundary — case-specific adaptation for important difference.

Related sources S15 S16

N22 · Do reported endpoints, times and analyses agree with the original plan?

Current findings: The evidence list’s registration field is null; the text does not claim to have read initial registration or a protocol. The abstract alone did not verify agreement with a registered 1st (primary) endpoint.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The required original plan is absent from the retained inputs.
Reason for missing information: Original plans, agreement of endpoints/analyses/times and reasons for amendments are unverified.
Required materials and conditions: Initial registration, protocol, analysis plan and amendment history.
Materials to obtain first: Initial registration, protocol, analysis plan and amendment history.
Further research: Compare prespecified endpoints, times and analyses in original plans with result tables/articles to review changes and possible selective reporting.
Remaining uncertainty: Original plans, agreement of endpoints/analyses/times and reasons for amendments are unverified.
Conditions for verification: Verify only the portions actually compared between original registration/protocol/analysis plan and reported LDL-C results.
Why this condition is needed: Needed to avoid establishing agreement with a registered 1st (primary) endpoint from the abstract/label alone.
Application exceptions: An NCT value of null does not establish nonregistration. An unavailable plan is not definitive evidence of selective reporting.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3: local application; M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design — case-specific adaptation for plans and registration.

Related sources S15 S16

N23 · At what level are the article and label linked to the same trial family?

Current findings: The S16 Morgan 1996 trial with 122 participants is strongly linked to S15 Table 3 by design/n/dose. The original citation limits this to less than a patient-level crosswalk. Original R1 records avoidance of double-counting the same trial arms.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: There is strong linkage evidence for the same key contrast, but no detailed trial/participant crosswalk.
Reason for missing information: Exact family correspondence across all label trial groups, patient-level crosswalks and the overall unique-trial count are unverified.
Required materials and conditions: Trial identifiers and population/arm/time crosswalks between the article and FDA trial tables.
Materials to obtain first: Trial identifiers and population/arm/time crosswalks between the article and FDA trial tables.
Further research: Review report–trial–outcome correspondence, distinguishing repeated citations of the same family from unconfirmed detailed links.
Remaining uncertainty: Exact family correspondence across all label trial groups, patient-level crosswalks and the overall unique-trial count are unverified.
Conditions for verification: Link matching design/n/dose in the article and regulatory table without inventing a patient-level crosswalk or 2 independent trials.
Why this condition is needed: Needed to avoid adding the article and FDA re-report as independent replications.
Application exceptions: The 2 bibliographic/regulatory reports are not 2 unique trials. Do not automatically merge other trial families in the full label into the same trial.
Referenced methods: M04 §4.6.1–4.6.2: distinction between studies and reports; cohort/outcome linkage is local application; M04 §4.6.1–4.6.2, M15 §15.3.1: local application — case-specific adaptation for reports and trial family.

Related sources S15 S16

N24 · Is independent replication of this question verified?

Current findings: Original R1 records avoiding double-counting the same trial arms. Multiple trials in the manufacturer table were not converted to R2 without verifying independent authors and funding.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: Independent author/funding records and unique result tables for the direct question were not acquired in the current inputs.
Reason for missing information: The number of independent direct replications and distribution of trial-specific conditions/results are unverified.
Required materials and conditions: Unique families, outcomes, funding and authorship for additional eligible trials.
Materials to obtain first: Unique families, outcomes, funding and authorship for additional eligible trials.
Further research: Compare eligible families, remove duplicate reports and record differences in conditions and unverified independence.
Remaining uncertainty: The number of independent direct replications and distribution of trial-specific conditions/results are unverified.
Conditions for verification: Link unique studies with the same product/population/measure to independent author and funding information.
Why this condition is needed: Needed to avoid automatically promoting multiple label trials or original R1 into an independent-replication count.
Application exceptions: Unavailable additional eligible material does not mean 0 studies worldwide or no effect.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1: local application; M04 §4.6.1–4.6.2: distinction between studies and reports; cohort/outcome linkage is local application; Chamgap’s own independence/attribution condition. The official methodological sections used in this pilot do not guarantee all these details — case-specific adaptation for independent replication.

Related sources S15 S16

N25 · Are research funding, product provision and author interests verified?

Current findings: The complete original article funding/COI statements were not accessed. Original I1 with uncertainty establishes neither manufacturer-only nor independent research.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The full declaration text is absent from the current retained scope.
Reason for missing information: Actual research funding, product provision, employment/patents and declared COI are unverified.
Required materials and conditions: Complete original article funding, product provision, employment/patents and COI declarations.
Materials to obtain first: Complete original article funding, product provision, employment/patents and COI declarations.
Further research: Compare original declarations with authors/institutions and study families, recording verified interests separately from uncertainty.
Remaining uncertainty: Actual research funding, product provision, employment/patents and declared COI are unverified.
Conditions for verification: Link actual full funding/COI declarations while retaining uncertainty about manufacturer-only or independent funding.
Why this condition is needed: Needed to avoid converting unavailable full text into certainty of manufacturer-only or independent research.
Application exceptions: Do not infer specific funding or the magnitude of bias from the NIASPAN product name or regulatory table alone.
Referenced methods: Chamgap’s own independence/attribution condition. The official methodological sections used in this pilot do not guarantee all these details — case-specific adaptation for funding and COI.

Related sources S16

N26 · Are the causes of inconsistent reports for other doses/endpoints verified?

Current findings: The retained record states that some publisher-abstract and regulatory-table values disagree, including 1000 mg LDL percentage change. Only the agreeing 2000 mg LDL −14% and each duration definition were adopted; inconsistencies of unknown cause were not asserted to be rounding.
Verification status: Conflicting data
Materials actually read: Retained summary read · external originals unread
Why unverified: The original inconsistency review explicitly records disagreement and unconfirmed causes.
Reason for missing information: The relevant original inconsistent values, phase/denominator crosswalks and causes/corrections are currently unverified. The agreeing 2000 mg LDL value itself was not marked as conflicting.
Required materials and conditions: Relevant original publisher-abstract/regulatory-table data, phases/denominators and corrections for 1000 mg LDL, TG and related values.
Materials to obtain first: Relevant original publisher-abstract/regulatory-table data, phases/denominators and corrections for 1000 mg LDL, TG and related values.
Further research: Compare dose, measure, time and denominator for each inconsistent item, distinguishing conflicting reports of the same contrast from values under different conditions.
Remaining uncertainty: The relevant original inconsistent values, phase/denominator crosswalks and causes/corrections are currently unverified. The agreeing 2000 mg LDL value itself was not marked as conflicting.
Conditions for verification: Retain the agreeing 2000 mg LDL value and mark the causes of actual inconsistencies for other doses/endpoints as unverified.
Why this condition is needed: Needed to avoid erasing related inconsistencies because some values agree or arbitrarily correcting them as rounding.
Application exceptions: A different dose alone is not automatically conflicting data. Retain only inconsistencies explicit in the current record; do not invent causes or new values.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3: state separation is locally designed; M04 §4.6.1–4.6.2, M15 §15.3.1: local application — case-specific adaptation for inconsistent reports.

Related sources S15 S16

N27 · Does LDL-C change answer whether myocardial infarction or mortality is prevented?

Current findings: The original key interpretation and reader answer distinguish lipid decreases from patient clinical benefit and do not interpret them as reduced myocardial infarction or mortality.
Verification status: Not applicable
Materials actually read: Retained summary read · external originals unread
Why unverified: The current main question concerns marker change and has not been extended to event prevention.
Reason for missing information: An event-trial requirement is inapplicable to this narrow question. Direct event prevention with the same strategy/population was not verified in this work.
Required materials and conditions: Direct event studies with the same strategy/population if extending to events or mortality.
Materials to obtain first: Direct event studies with the same strategy/population if extending to events or mortality.
Further research: If an extension is claimed, review event-study populations, formulations, comparators and durations in a separate eligibility table.
Remaining uncertainty: An event-trial requirement is inapplicable to this narrow question. Direct event prevention with the same strategy/population was not verified in this work.
Conditions for verification: Separate the lipid-change question from event/mortality questions.
Why this condition is needed: Needed to avoid automatically converting surrogate improvement into prevention of clinical events.
Application exceptions: Do not require an event trial for the narrow LDL-C percentage-change question. This table does not assess event prevention.
Referenced methods: M03 §3.2.4: locally defined extension boundary — case-specific adaptation for extension to clinical events.

Related sources S15 S16

N28 · Does the result answer questions about optimal dose, long-term maintenance or specific subgroups?

Current findings: The current scope is 2000 mg/day versus diet plus placebo over 16 weeks including titration. The 1000 mg arm is a supporting record; do not create a pooled mean, optimal dose or long-term effect.
Verification status: Not applicable
Materials actually read: Retained summary read · external originals unread
Why unverified: Optimal dose, long-term persistence and subgroups are extensions of the selected question and are not claimed in this table.
Reason for missing information: The extension requirement is inapplicable. Direct effects on optimal dose, long-term maintenance and subgroups were not newly verified.
Required materials and conditions: Direct dose comparisons, long-term follow-up and prespecified subgroup/interaction data if extending the claim.
Materials to obtain first: Direct dose comparisons, long-term follow-up and prespecified subgroup/interaction data if extending the claim.
Further research: Review direct comparisons, follow-up and interactions separately for extensions outside the original question; do not average supporting arms of the same trial.
Remaining uncertainty: The extension requirement is inapplicable. Direct effects on optimal dose, long-term maintenance and subgroups were not newly verified.
Conditions for verification: Do not extend the fixed-comparison 16-week result to optimal dose, long-term persistence or effect modification.
Why this condition is needed: Needed to avoid transferring one key dose/period to optimization or maintenance effects.
Application exceptions: The presence of a 1000 mg arm does not establish an optimal dose. Do not require every long-term/subgroup study for the narrow 16-week question.
Referenced methods: M03 §3.2.1–3.2.4: dose, duration and effect-modification details are locally designed — case-specific adaptation for dose and long-term extensions.

Related sources S15 S16

N29 · Are arm-specific harm collection, event/person counts and stopping denominators verified for the key trial?

Current findings: Warnings about flushing and elevated liver enzymes, glucose and urate at prescription doses are retained. Arm-specific AE denominators in the key small trial are unconfirmed; FDA2020 pooled data were not used as this trial’s event rates.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: The official document’s warning scope is linked; systematic collection/counts in the selected trial remain unresolved.
Reason for missing information: AE people/events, stopping, arm-specific denominators/time and complete collection scope in the selected trial are unverified.
Required materials and conditions: The key trial’s AE definitions, collection, people/events, stopping, exposure time and arm-specific denominators.
Materials to obtain first: The key trial’s AE definitions, collection, people/events, stopping, exposure time and arm-specific denominators.
Further research: Link arm-specific safety tables/collection procedures to follow-up and check which trials contribute to FDA pooled data.
Remaining uncertainty: AE people/events, stopping, arm-specific denominators/time and complete collection scope in the selected trial are unverified.
Conditions for verification: Separate original warnings from actual arm-specific harm counts in the key small trial; do not use pooled data as trial event rates.
Why this condition is needed: The presence of efficacy data or regulatory warnings does not establish complete harm counts in the same trial.
Application exceptions: Do not use FDA2020 pooled safety data as event rates in this trial or convert unverified harms into harmlessness or AE0.
Referenced methods: M19 §19.1.2–19.2.4: local application; M19 §19.1.2–19.2.4: detailed distinctions are locally designed; M19 §19.1.2–19.2.4, M04 §4.6.3: local application — case-specific adaptation for harm collection and denominators.

Related sources S15

N30 · Are temporal order, co-treatment and alternative comparative causes verified for harms in the selected trial?

Current findings: The original safety detail retains warnings about pharmacological-dose nicotinic acid but leaves selected-trial arm-specific harm denominators unconfirmed. Actual temporal order, co-treatment/alternatives and stopping/recovery outcomes are not verified in these inputs.
Verification status: Unverified
Materials actually read: Retained summary read · external originals unread
Why unverified: The current warning summary does not provide selected-trial timing, comparative or alternative-cause data.
Reason for missing information: Temporal order, co-treatment/alternatives, comparisons/causality and long-term vulnerable-group scope for selected-trial harms are unverified.
Required materials and conditions: Trial AE onset, stopping/recovery, concurrent medication/baseline disease, comparisons and long-term vulnerable-group data.
Materials to obtain first: Trial AE onset, stopping/recovery, concurrent medication/baseline disease, comparisons and long-term vulnerable-group data.
Further research: Link exposure/event timelines and co-treatment to actual counts and review the possible scope of causal, frequency and long-term extrapolation.
Remaining uncertainty: Temporal order, co-treatment/alternatives, comparisons/causality and long-term vulnerable-group scope for selected-trial harms are unverified.
Conditions for verification: Link warnings to actual timing, comparisons and alternatives in the same population/exposure, without converting a signal to a causal rate.
Why this condition is needed: Needed to avoid automatically extending label warnings to causal risk estimates or overall safety in the selected trial.
Application exceptions: Do not invent rechallenge, recovery, incidence or rare long-term-risk values from a summary without event counts. No H07 independent replicated-harm claim is made in this work.
Referenced methods: M19 §19.1.2–19.2.4: local application; M19 §19.2: design-specific harm questions, with locally designed temporal details; M19 §19.2.2–19.2.4, M03 §3.2.3: local application; M19 §19.2.2–19.2.4: design considerations, with locally designed confounding records; Chamgap’s own interpretive boundary. M19 principles inform this work; no official causality tool was executed — case-specific adaptation for harm timing and alternatives.

Related sources S15

N31 · Within what scope was reported laboratory interference verified?

Current findings: The current text includes specific laboratory-interference warnings and the original citation links FDA Section 7.6, printed page 9. This summary lacks assay-specific details and evidence of actual LDL-C interference in the selected trial.
Verification status: Partly verified
Materials actually read: Retained summary read · external originals unread
Why unverified: Warnings and historical locations are verified; assay-specific details and actual trial interference remain unresolved.
Reason for missing information: Assay-specific interference conditions and actual interference in selected-trial LDL-C testing are unverified.
Required materials and conditions: FDA7.6 assay-specific interference conditions and the original trial LDL-C assay/interference observations.
Materials to obtain first: FDA7.6 assay-specific interference conditions and the original trial LDL-C assay/interference observations.
Further research: Compare assay-specific conditions in the official document with original measurement methods, separating general warnings from interference observed in the trial.
Remaining uncertainty: Assay-specific interference conditions and actual interference in selected-trial LDL-C testing are unverified.
Conditions for verification: Do not convert original assay-specific warnings into actual LDL-C measurement errors or effects on all tests.
Why this condition is needed: Needed to avoid extending label interference warnings to invalidation of this trial’s LDL-C effect or interference with all tests.
Application exceptions: Do not add test names, mechanisms or frequencies absent from the original inputs or assert that LDL-C interference occurred.
Referenced methods: M19 §19.1.2–19.2.4: local application; M19 §19.1.2–19.2.4: detailed distinctions are locally designed; Chamgap’s own interpretive boundary. M19 principles inform this work; no official causality tool was executed; M08 Table 8.2.a, M03 §3.2.4: local application — case-specific adaptation for laboratory interference.

Related sources S15

N32 · Which material was actually read in this work?

Current findings: The complete original-byte retained summary was read in this work. Historical access was S15 regulatory PDF text/selected table screenshots and S16 abstract/bibliography. External PDFs and publisher/DOI pages were not attempted, acquired or read in this work; individual access dates remain null.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: Current actual reading and original recorded access levels were separately connected by material.
Reason for missing information: The current retained-summary reading scope was verified. Current access to external originals, physical/identifier agreement, full text and licensing were not verified.
Required materials and conditions: Current input SHA, material type/URL, historical access locations, individual access dates and global review date.
Materials to obtain first: Current input SHA, material type/URL, historical access locations, individual access dates and global review date.
Further research: Compare existence, acquisition, reading status and original locations by report, separating blue summary links from unread external full texts.
Remaining uncertainty: The current retained-summary reading scope was verified. Current access to external originals, physical/identifier agreement, full text and licensing were not verified.
Conditions for verification: Distinguish original-byte retained summaries, historical access in original citations and current external access not attempted/unread for each material.
Why this condition is needed: Needed to avoid converting reading of the retained summary into current reading of FDA PDFs, articles or DOI-linked full texts.
Application exceptions: Citations have no individual access dates. Do not infer that the 2026-09-14 review date was an actual access date or automatically inherit report access for the DOI entry.
Referenced methods: M04 §4.5–4.6: material-collection/selection principles; access/reading separation and the hyperlink contract are locally designed; M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design — case-specific adaptation for material reading.

Related sources S15 S16

N33 · What search, correction and history scope is retained?

Current findings: The original search is described as 2026-09-14 web indexing, a supplied index of 3081 entries/related originals and direct publisher/FDA/NHLBI sources. It was not a complete systematic PubMed search or exhaustive search of unpublished material; original wording/references for 5 corrections remain unchanged.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: The reported scope of earlier searches/corrections and the boundary of work not performed now were verified.
Reason for missing information: Separate old search/verification/shared-correction originals and current unpublished/registration, correction or retraction checks were not reviewed in this work.
Required materials and conditions: Existing search records, 5 corrections, inputs used and the unpublished/registration verification scope.
Materials to obtain first: Existing search records, 5 corrections, inputs used and the unpublished/registration verification scope.
Further research: Check the scope actually retained for search logs/corrections and limit uncertainty statements to the relevant sections/dates.
Remaining uncertainty: Separate old search/verification/shared-correction originals and current unpublished/registration, correction or retraction checks were not reviewed in this work.
Conditions for verification: Distinguish the 2026-09-14 web indexing/existing searches/corrections from this local conversion.
Why this condition is needed: Needed to avoid promoting old internal validation/web indexing to a current exhaustive clinical search.
Application exceptions: Separate original verification reports, source lists and shared correction records were not opened in this work; S17/S19 without citations are not made into new reports.
Referenced methods: M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design; M04 §4.6.3, M15 §15.3.1–15.3.3: state separation is locally designed; M08 Table 8.2.a, M04 §4.6.3: local application — case-specific adaptation for verification scope and history.

Related sources S15 S16

N34 · How are original assessments/numbers distinguished from table-review status?

Current findings: Original grade C/score 46, B/S/R1/I1/EX/B1/CX, caution and all nulls/corrections/historical arithmetic remain unchanged. Condition states indicate item-specific verification within current retained material, not a new clinical assessment or success probability.
Verification status: Met
Materials actually read: Retained summary read · external originals unread
Why unverified: Original current values and limits of table conversion/condition states were separately recorded.
Reason for missing information: Original-value preservation and the production-review scope were verified. Independent clinical certification, official methodological assessment and current external full-text verification were not performed. The earlier unpublished-website record describes its historical state, distinct from current publication status.
Required materials and conditions: Original grade/score/axes, calculation records, gaps, corrections and original internal-review metadata.
Materials to obtain first: Original grade/score/axes, calculation records, gaps, corrections and original internal-review metadata.
Further research: Compare the complete retained summary with derived tables, separating technical checks from content review of unchanged original values/nulls, inconsistencies and condition states.
Remaining uncertainty: Original-value preservation and the production-review scope were verified. Independent clinical certification, official methodological assessment and current external full-text verification were not performed. The earlier unpublished-website record describes its historical state, distinct from current publication status.
Conditions for verification: Retain C46, original axes/EX/CX, original caution, nulls and historical arithmetic; table-preparation verification is not efficacy/safety certification.
Why this condition is needed: Needed to avoid interpreting blue verification in the table as a new clinical-efficacy grade, fulfilment percentage or official certification.
Application exceptions: Original document-quality A and internal validation are distinct from evidence C/46. Table preparation, another author’s QA, technical/UI checks and publication are also separate statuses.
Referenced methods: M03 §3.1, §3.2.1–3.2.4: question-clarification principles; detailed separation rules are locally designed; M04 §4.5, §4.6.3: current-record conversion limits derive from user scope and local design; M15 §15.3.1–15.3.3: local application; Chamgap’s own interpretive boundary. M19 principles inform this work; no official causality tool was executed — case-specific adaptation for original assessment and table status.

Related sources S15 S16